December 6, 2021

Anaqua and ASU Co., Ltd. Announce Strategic Partnership

Long-term partnership to provide Anaqua intellectual property management systems migration and support for clients in Japan TOKYO, Dec. 06, 2021 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property management solutions, and ASU Co., Ltd. (ASU), one of the foremost companies in Japan providing support for IP

>

Nasdaq Survey Uncovers Portfolio Managers’ Top Data Infrastructure Challenges

Quantitative managers cite inadequate manpower as source of dissatisfaction; fundamental managers cite inability to quickly onboard and deploy data Processes managers are already or are considering outsourcing… NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq: NDAQ) today released results from a survey of portfolio managers across the

>

Helsinn Achieves Carbon Neutrality

Helsinn Achieves Carbon Neutrality Lugano, Switzerland, December 6, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces that it has achieved carbon neutrality for the first time. Since 2012, Helsinn has been committed to becoming more sustainable. Our environmental performance

>

Wood Mackenzie Appoints Elena Belletti as Head of Carbon Research

Joins from United Nations to lead growing carbon team Elena Belletti, Head of Carbon Research, Wood Mackenzie, a Verisk business LONDON/HOUSTON/SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) — Wood Mackenzie, a Verisk business (Nasdaq:VRSK), has appointed Elena Belletti as Head of Carbon Research within the company’s Energy Transition Practice. Based in

>

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age group SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the

>